Xvivo Perfusion AB (SE:XVIVO)
:XVIVO
Want to see SE:XVIVO full AI Analyst Report?
Earnings Data
Report Date
Jul 10, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.83Last Year’s EPS
0.05Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong operational momentum: record sales, double-digit organic growth across thoracic and abdominal, robust EVLP consumable growth (+56%), a compelling clinical evidence package for the Heart Assist (reduced severe PGD and improved 1-year survival), rapid Flowhawk adoption (+62%), and positive cash flow for the second consecutive quarter. Headwinds were primarily margin pressure in abdominal and services (organ recovery), dependency on regulatory approvals for broader heart and liver commercialization, one-time go-to-market costs (SEK 7m), and some revenue concentration risk in EVLP. Overall the positive commercial and clinical developments and improving cash generation outweigh the manageable operational and regulatory risks.Company Guidance
Record Sales and Strong Top-Line Growth
Net sales of SEK 241 million in Q1 2026 with organic top-line growth of 23% (18% excluding U.S. CAP trial revenue). Management described this as a record quarter with broad-based momentum across core businesses.
Profitability and Cash Flow
EBITDA of 21% for the quarter (24% underlying excluding SEK 7m nonrecurring heart go-to-market costs); EBIT 13%. Operating cash flow SEK 65 million and positive total cash flow for the second consecutive quarter; cash position SEK 308 million at quarter end.
Thoracic Segment Outperformance
Thoracic sales SEK 160 million with organic growth of 27% (19% excluding CAP revenue). Thoracic gross margin strong at 83% driven by pricing actions and product mix.
EVLP Momentum — Consumables and Hub Model
EVLP disposables grew 56% in Q1. Successful OPO EVLP hub pilot (10 EVLPs performed); second OPO onboarded in early Q2 and 4–5 additional OPOs identified in rollout pipeline, supporting continued EVLP adoption.
Kidney Sales Surge
Abdominal net sales SEK 66 million with organic growth 24%; kidney sales up 63% in local currencies, driven by growing interest for Kidney Assist Transport in North America (U.S. and Canada) and new accounts.
Flowhawk Rapid Adoption
Services software Flowhawk grew 62% in Q1 and is now implemented at 6 of the 10 largest U.S. transplant programs, indicating strong enterprise adoption potential.
Compelling Clinical Data for Heart
U.S. PRESERVE trial (141 patients, 14 sites) met predefined efficacy and safety endpoints; severe PGD 7.9% in U.S. data. European randomized trial: ex vivo group reduced severe PGD by 76% (20%→5%) and achieved a 6% absolute increase in 1-year survival; primary endpoint statistically significant at day 365. European DCD direct procurement proof-of-concept: 30-day survival 98%, severe PGD 5%.
Regulatory and Market Access Progress
Heart machine and disposables CE-marked; compassionate-use sales in Europe and Australia already occurring. U.S. heart regulatory file being prepared for FDA submission (planned for summer). Liver Assist holds FDA Breakthrough Device designation, approved IDE and CMS funding; company preparing for QSA discussion on U.S. regulatory route.
SE:XVIVO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SE:XVIVO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 24, 2026 | kr300.00 | kr282.40 | -5.87% |
Jan 27, 2026 | kr218.80 | kr226.60 | +3.56% |
Oct 23, 2025 | kr179.50 | kr182.40 | +1.62% |
Jul 11, 2025 | kr299.20 | kr201.40 | -32.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Xvivo Perfusion AB (SE:XVIVO) report earnings?
Xvivo Perfusion AB (SE:XVIVO) is schdueled to report earning on Jul 10, 2026, TBA (Confirmed).
What is Xvivo Perfusion AB (SE:XVIVO) earnings time?
Xvivo Perfusion AB (SE:XVIVO) earnings time is at Jul 10, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Xvivo Perfusion AB stock?
The P/E ratio of Xvivo Perfusion AB is N/A.
What is SE:XVIVO EPS forecast?
SE:XVIVO EPS forecast for the fiscal quarter 2026 (Q2) is 0.83.